NYLIM
PRLD icon

New York Life Investment Management’s Prelude Therapeutics PRLD Stock Holding History

New York Life Investment Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-82,000
Closed -$495K – 1346
2022
Q4 		$495K Buy
82,000
+8,607
+12% +$55.2K 0.01% 941
2022
Q3 		$485K Buy
73,393
+5,808
+9% +$39.2K 0.01% 767
2022
Q2 		$353K Buy
+67,585
New +$344K ﹤0.01% 1081

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New York Life Investment Management's PRLD Position: Q1 2023 in Review

New York Life Investment Management sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 82,000 shares — an estimated $495K sold.

New York Life Investment Management first reported a position in PRLD in Q2 2022 and held it in 3 quarters. The position peaked at $495K in Q4 2022. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • New York Life Investment Management reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 82,000 Prelude Therapeutics shares in Q1 2023, an estimated $495K.
  • New York Life Investment Management first reported a position in Prelude Therapeutics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Prelude Therapeutics position peaked at $495K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.